Skip to main content

Paul Galatsis, PhD

Senior Principal Scientist at Pfizer Worldwide Research and Development

Location: Groton, CT United States

Paul Galatsis, PhD, received an Honors B.Sc. in biochemistry with distinction from the University of Guelph (Canada) in 1981. As a Natural Sciences and Engineering Council (NSERC) - Canada postgraduate fellow, Dr. Galatsis earned a PhD from Indiana University in 1987 and conducted postdoctoral research, as an NSERC postdoctoral fellow, at The Ohio State University. Returning to Canada in 1989, Dr. Galatsis began his independent, externally funded research career as an assistant professor at the University of Guelph. He was promoted to associate professor (with tenure) in 1994. Dr. Galatsis gave up his academic appointment in 1996 to take a research position in neurosciences chemistry with Parke-Davis Pharmaceutical Research in Michigan, and later transferred to the Pfizer Groton Laboratories. He has led or contributed to multiple projects targeting neurodegenerative, psychiatric and inflammatory diseases. Dr. Galatsis’ contributions to Pfizer’s drug discovery efforts have been recognized with team awards and the Pfizer R&D Achievement Award.

Associated Grants

  • Shoring Up a Medical Chemistry Approach to Treating Parkinson’s Disease: The Bridge Initiative


  • LRRK2 PET Tracer Development


  • Development of LRRK2 Target Engagement Ligands


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.